CHADS2 score in predicting cerebrovascular events - A meta-analysis

Arquivos Brasileiros de Cardiologia

Volumn 100, Issue 3, 2013, Pages 294-301

  Santos, Cristina ^a   Pereira, Telmo ^a,b   Conde, Jorge ^a  

^a Escola Superior de Tecnologia da Saúde de Coimbra   (Portugal)

^b Universidade Metodista de Angola   (Portugal)

Author keywords

Atrial fibrillation; Meta analysis; Prognosis; Risk factors; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; WARFARIN;

BLOOD CLOTTING; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHADS2 SCORE; DEATH; DISEASE ASSOCIATION; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; META ANALYSIS; MORBIDITY; MORTALITY; PUBLICATION; REVIEW; RISK FACTOR; SURVIVAL RATE;

EID: 84876548479     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.5935/abc.20130068     Document Type: Review

References (17)

1. Correia M, Silva MR, Matos I, Magalhães R, Lopes JC, Ferro JM, et al. Prospective community-based study of stroke in Northern Portugal: incidence and case fatality in rural and urban populations. Stroke. 2004;35(9):2048-53.
2. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al; European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12(10):1360-420.
3. Crandall MD, Horne B, Day J, Anderson J, Muhlestein J, Crandall B, et al. Atrial fibrillation and CHADS2 risk factors are associated with highly sensitive C-reactive protein incrementally and independently. Pacing Clin Electrophysiol. 2009;32(5):648-52.
4. Maehama T, Okura H, Imai K, Yamada R, Obase K, Saito K, et al. Usefulness of CHADS2 score to predict C-reactive protein, left atrial blood stasis, and prognosis in patients with nonrheumatic atrial fibrillation. Am J Cardiol. 2010;106(4):535-8.
5. Mélon P, Lancellótti P. [2010 European guidelines for antithrombotic therapy in patients with atrial fibrillation and new risk score for the assessment of the risk of bleeding]. Rev Med Liege. 2010;65(10):580-2.
6. Ad N, Henry L, Schlauch K, Holmes SD, Hunt S. The CHADS score role in managing anticoagulation after surgical ablation for atrial fibrillation. Ann Thorac Surg. 2010;90(4):1257-62.
7. Crandall MA, Horne BD, Day JD, Anderson JL, Muhlestein JB, Crandall BG, et al. Atrial fibrillation significantly increases total mortality and stroke risk beyond that conveyed by the CHADS2 risk factors. Pacing Clin Electrophysiol. 2009;32(8):981-6.
8. Lang S, Ederhy S, Boyer-Chatene L, Dufaitre G, Di Angelantonio E, Meuleman C, et al. CHADS2 Score predicts the occurrence of death, stroke and heart failure in patients with atrial fibrillation: a single-center cohort study. J Am Coll Cardiol. 2010;55(10 s1):A8. E79-A8. E79.
9. Rietbrock S, Heeley E, Plumb J, van Staa T. Chronic atrial fibrillation: incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am Heart J. 2008;156(1):57-64.
10. Daccarett M, Badger TJ, Akoum N, Burgon NS, Mahnkopf C, Vergara G, et al. Association of left atrial fibrosis detected by delayed-enhancement magnetic resonance imaging and the risk of stroke in patients with atrial fibrillation. J Am Coll Cardiol. 2011;57(7):831-8.
11. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864-70.
12. Sandhu RK, Bakal JA, Ezekowitz JA, McAlister FA. Risk stratification schemes, anticoagulation use and outcomes: the risk--treatment paradox in patients with newly diagnosed non-valvular atrial fibrillation. Heart. 2011;97(24):2046-50.
13. Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, et al; RE-LY Investigators. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med. 2011;155(10):660-7.
14. Henriksson KM, Farahmand B, Johansson S, Asberg S, Terént A, Edvardsson N. Survival after stroke--the impact of CHADS2 score and atrial fibrillation. Int J Cardiol. 2010;141(1):18-23.
15. Masaki N, Suzuki M, Iwatsuka R, Mizukami A, Kumasaka L, Nagahori W, et al. Effectiveness of risk stratification according to CHADS2 score in Japanese patients with nonvalvular atrial fibrillation. Int Heart J. 2009;50(3):323-9.
16. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009,339:b2700.
17. Moulton AW, Singer DE, Haas JS. Risk factors for stroke in patients with nonrheumatic atrial fibrillation: a case-control study. Am J Med. 1991;91(2):156-61.